Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

Inclusion Criteria: * Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age. * Migraine attacks, on average, lasting about 4 - 72 hours if untreated. * 4 to 14 migraine days per month on average across the 3 months prior to the Screening Visit (month is defined as 28 days for the purpose of this protocol). * Less than 15 headache days (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and throughout the Screening Phase. * Subjects must be able to distinguish migraine attacks from tension/cluster headaches. * Subjects on prophylactic migraine medication (excluding CGRP antagonists) are permitted to remain on therapy if they have been on a stable dose for at least 3 months (12 weeks) prior to the Screening Visit, and if the dose is not expected to change during the course of the study. * Triptan unsuitable Exclusion Criteria: -Target Disease Exclusion: 1. History of cluster headache, basilar migraine, or hemiplegic migraine 2. Current medication overuse headaches 3. Headaches occurring 15 or more days per month (migraine or non-migraine) in any of the 3 months prior to the Screening Visit 4. Active chronic pain syndrome (such as fibromyalgia, chronic pelvic pain, complex regional pain syndrome \[CRPS\]) 5. Other pain syndromes (including trigeminal neuralgia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, interfere with study assessments of safety or efficacy